FDA Approves Selpercatinib for Pediatric Patients With RET-Altered Metastatic Thyroid Cancer, Solid Tumors

The FDA granted accelerated approval to selpercatinib (Retevmo) for the treatment of pediatric patients aged 2 years and older with RET-altered metastatic thyroid cancer or solid tumors.